User profiles for ANTONIO MARCHESONI

Marchesoni Antonio

Reumatologo, Humanitas, Milano
Verified email at sanpiox.humanitas.it
Cited by 11482

Classification criteria for psoriatic arthritis: development of new criteria from a large international study

…, D Gladman, P Helliwell, A Marchesoni… - … : Official Journal of …, 2006 - Wiley Online Library
Objective. To compare the accuracy of existing classification criteria for the diagnosis of
psoriatic arthritis (PsA) and to construct new criteria from observed data. Methods. Data were …

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

…, YJ Lee, E Lubrano, A Marchesoni… - Annals of the …, 2013 - ard.bmj.com
Objective To develop new composite disease activity indices for psoriatic arthritis (PsA).
Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. …

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in …

…, R Gorla, M Govoni, G Lapadula, A Marchesoni… - Autoimmunity …, 2012 - Elsevier
OBJECTIVE: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF
therapy on the basis of the data included in the GISEA register. METHODS: The study …

Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis

L Scotti, M Franchi, A Marchesoni, G Corrao - Seminars in Arthritis and …, 2018 - Elsevier
Background Psoriatic arthritis (PsA) is a specific form of inflammatory arthritis associated with
psoriasis affecting in the same measure men and women but with a consistent geographic …

A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.

…, P Macchioni, I Olivieri, A Marchesoni… - The Journal of …, 2001 - jrheum.org
OBJECTIVE: To compare the efficacy and tolerability of cyclosporine (CSA) with that of
symptomatic therapy (ST) alone and sulfasalazine (SSZ) in the treatment of psoriatic arthritis (PsA)…

Serious infections during anti-TNFα treatment in rheumatoid arthritis patients

…, FB Pallavicini, R Gorla, M Filippini, A Marchesoni - Autoimmunity …, 2009 - Elsevier
The objective was to estimate the incidence of serious infections in the patients treated with
anti-TNFα agents for rheumatoid arthritis (RA) recorded in the Lombardy Rheumatology …

TNF‐α antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice

A Marchesoni, E Zaccara, R Gorla… - Annals of the New …, 2009 - Wiley Online Library
A cohort of rheumatoid arthritis (RA) patients in the Lombardy Rheumatology Network (LOHREN)
registry and receiving anti‐TNF therapy was evaluated after 6, 12, 24, and 36 months. …

Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study

…, C Sardu, I Ujfalussy, R Scarpa, A Marchesoni… - The Journal of …, 2011 - jrheum.org
Objective. During OMERACT 8, delegates selected patient global assessment (PGA) of
disease as a domain to be evaluated in randomized controlled trials in psoriatic arthritis (PsA). …

Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal

…, FB Pallavicini, M Filippini, R Gorla, A Marchesoni… - Autoimmunity …, 2009 - Elsevier
It has been found that tumour necrosis factor(TNF)-alpha plays a pivotal role in the pathogenesis
of rheumatoid arthritis (RA), and the development of drugs targeting this molecule has …

Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of …

…, R Gerli, AR Giardina, A Marchesoni… - The Journal of …, 2012 - jrheum.org
Objective. To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors
adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid arthritis (…